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Research
Epidemiologic evidence is the most relevant
type of evidence for risk assessment, because
limited extrapolation is needed to apply study
results to a real-life situation. However, because
of ethical considerations epidemiologic assess-
ment of risk of potential hazardous exposures is
most often limited to observational studies.
This deviation from experimental study condi-
tions (e.g., randomized clinical trials) requires
careful evaluation of the quality of the observa-
tional evidence. A major issue in human obser-
vational studies (HOS) is the more limited
control of circumstances under which studies
are performed leading to a potential bias in the
estimated association between exposure and
health outcome. The quality of the design and
conduct of a study affects the potential for bias
in the study results and thus the value for risk
assessment. In quantitative risk assessment
(QRA), exposure–response relations are deﬁned
in quantitative terms (i.e., risk per unit of expo-
sure). HOS that conducted quantitative
exposure–response analysis (i.e., a quantitative
description of the relation between exposure to
a hazardous agent and a speciﬁc health effect)
can contribute directly to QRA. Therefore, the
quality of quantitative exposure assessment is
crucial to HOS used in QRA. In recent years,
several frameworks have been developed to
assess the quality of HOS for risk assessment
[Goldbohm et al. 2006; Hertz-Picciotto 1995;
Money and Margary 2002; Shore et al. 1992;
Swaen 2006; van den Brandt et al. 2002;
World Health Organization (WHO) Working
Group 2000]. These frameworks have provided
broad overviews of different aspects that con-
tribute to HOS quality. However, the existing
frameworks lack a speciﬁc focus on the evalua-
tion of exposure assessment in HOS for QRA.
We developed a structured framework with
guidelines for the evaluation of HOS in QRA
that have a speciﬁc focus on the evaluation of
the exposure assessment component of HOS.
The approach incorporates exclusion of HOS
that do not meet the minimal quality required
for QRA and ranking based on the quality of
the design, conduct, and reporting of the HOS
that do meet the minimal quality required for
QRA. Subsequently, to demonstrate its useful-
ness, we applied the framework to all case–
control and cohort studies on the relation
between exposure to benzene and acute
myeloid leukemia (AML).
Deﬁnition of Terms Related 
to Quantiﬁcation of Exposure
in QRA
The exposure evaluation guidelines are related
largely to the assessment and assignment of
exposure. Exposure assessment is defined as
estimation of the concentration of an agent in
a specific medium (e.g., air or soil) during a
speciﬁc time period (e.g., a working day) and
under specific conditions (e.g., type of
weather) (Zartarian et al. 1997). Examples are
the concentration of respirable crystalline sil-
ica to which a worker was exposed in his
breathing zone on a speciﬁc day performing a
speciﬁc task, or the level of caffeine in a single
cup of coffee. The most direct strategy for
exposure assessment is to perform quantitative
measurements. However, in many HOS,
exposure measurements are scant, and other
sources of information (e.g., expert judgment,
questionnaire data, or predictive models) are
used to assess exposure (Ott 2005). Exposure
assignment is deﬁned as the step where expo-
sure estimates are assigned to the individuals
in the study population based on information
on, for instance, jobs held or food frequency
questionnaires (Loomis and Kromhout 2004).
Description of the Framework
and Evaluation Guidelines
The criteria that together form the guidelines
for evaluation of HOS for QRA are described
in detail in the Supplemental Material
[see Supplemental Material I, Evaluation
Guidelines (http://www.ehponline.org/
members/2008/11530/suppl.pdf) for details].
Here we provide an overview of the structure
of the framework and discuss the evaluation
criteria that are crucial for the quality of the
assessment and assignment of exposure. The
framework is based on three tiers (Figure 1).
The criteria in the first tier are used to
exclude studies not suitable for QRA and
should be applied to all HOS considered for
QRA (Table 1). The questions in tier I are all
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BACKGROUND: Careful evaluation of the quality of human observational studies (HOS) is required
to assess the suitability of HOS for quantitative risk assessment (QRA). In particular, the quality of
quantitative exposure assessment is a crucial aspect of HOS to be considered for QRA.
OBJECTIVE: We aimed to develop guidelines for the evaluation of HOS for QRA and to apply these
guidelines to case–control and cohort studies on the relation between exposure to benzene and
acute myeloid leukemia (AML).
METHODS: We developed a three-tiered framework speciﬁc for the evaluation of HOS for QRA and
used it to evaluate HOS on the relation between exposure to benzene and AML. 
RESULTS: The developed framework consists of 20 evaluation criteria. A speciﬁc focus of the frame-
work was on the quality of exposure assessment applied in HOS. Seven HOS on the relation of
benzene and AML were eligible for evaluation. Of these studies, ﬁve were suitable for QRA and
were ranked based on the quality of the study design, conduct, and reporting on the study.
CONCLUSION: The developed guidelines facilitate a structured evaluation that is transparent in its
application and harmonizes the evaluation of HOS for QRA. With the application of the guide-
lines, it was possible to identify studies suitable for QRA of benzene and AML and rank these stud-
ies based on their quality. Application of the guidelines in QRA will be a valuable addition to the
assessment of the weight of evidence of HOS for QRA.
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design, the quality of conduct, and the quality
of the reporting of HOS. Therefore, HOS are
suitable for QRA only if all questions are
answered afﬁrmatively. A negative answer to
one of the questions should result in exclusion
of the HOS for QRA.
In the second tier, the HOS are categorized
based on the type of study design (Table 1).
The reason for categorization in tier II is 2-fold:
exclusion of HOS that have an inappropriate
study design for QRA, and selection of appro-
priate criteria for further evaluation in tier III.
In the third tier, a decision is made whether to
include HOS in QRA based on a set of design
speciﬁc criteria. A distinction is made between
the criteria intended to assess whether HOS are
suitable for QRA and the criteria intended to
be used in ranking of the HOS suitable for
QRA based on the quality aspects of these
HOS. Some criteria in Table 1 are used in both
the selection and ranking of HOS. Although
this framework has been developed primarily to
facilitate objective evaluation of HOS for QRA,
the criteria in the framework can also be used as
guidelines for the conduct of high-quality HOS
suitable for future QRA. To facilitate transpar-
ent and objective evaluation of evidence from
HOS, risk assessors should a priori deﬁne mini-
mum requirements for including a study in
QRA, such as a priori deﬁnitions of acceptable
levels of the response rate and loss to follow-up.
In addition, the minimal follow-up time
required to detect the health effect of interest
should be deﬁned. Finally, all relevant potential
strong confounding factors should be identi-
ﬁed. The actual operational deﬁnition of these
requirements will need to be on a case-by-case
basis depending on the specific exposure–
response relation studied.
Criteria related to the quality of assess-
ment and assignment of exposure of HOS.
Is exposure expressed on a ratio scale and
speciﬁc for the agent of interest? If exposure
is expressed on a ratio scale, the units of the
scale represent the same magnitude of expo-
sure across the whole range of the scale, and a
rational zero is included (Stevens 1946).
Quantitative exposure measurements, there-
fore, should be at the basis of exposure assess-
ment. HOS that present quantitative exposure
estimates based solely on expert judgment
should not be used in QRA because of difﬁ-
culties with regard to calibration of these esti-
mates. For QRA, the exposure measures
reported in HOS need to be specific for the
agent of interest. Only a highly speciﬁc meas-
ure of exposure can be used to demonstrate a
potential causal relation between exposure and
health effect.
Quality of the exposure measurement
methods. Quantitative measurements used in
the exposure assessment in HOS can poten-
tially differ with regard to the quality of the
measurement methods and the analytical
methods used. A guideline to evaluate HOS
based on the quality of exposure measurements
is to compare the method(s) used in the study
to the method(s) that are currently considered
as best practice. Some studies provide informa-
tion on side-by-side comparisons of the expo-
sure measurement method used with the best
practice at the time of the study. Additional
information from studies that focus solely on
side-by-side comparisons of exposure measure-
ment methods can be used as well (de Vocht
et al. 2006; Stephenson et al. 2004).
Insight in the variability of exposure. For
the evaluation of HOS, it is important to real-
ize that exposure measurements used in expo-
sure assessment can be highly variable in level.
This variability can be attributed to a combi-
nation of variation in exposure levels over time
and space. Advanced methodologies to acquire
insight in the level of measurement variability
on HOS outcomes have been proposed
(Heederik and Miller 1988; Kromhout et al.
1999; Loomis et al. 1998; Xue et al. 2006).
Before the evaluation, risk assessors must
deﬁne a minimum acceptable level of informa-
tion required to assess whether enough insight
in variability of exposure measurements is pro-
vided in HOS. Tielemans et al. (2002) have
developed guidelines to evaluate exposure data
from HOS performed in the occupational
exposure context. Similar approaches should
be applied to exposure data from other expo-
sure contexts (e.g., dietary exposure, consumer
exposure). Differences between HOS in the
ability to assess the relative contribution of the
different sources of variability in exposure
measurements can be used to rank the HOS.
Application of exposure measurements
in exposure assessment. In most HOS,
researchers are confronted with a scarcity of
exposure measurements. As a result, exposure
measurements might not be available for each
assignment unit (i.e., a single individual or a
group of individuals with assumed similar expo-
sure patterns) for the complete time period of
interest. In this situation, exposure measure-
ments performed for assignment unit–time
period combinations and information regarding
the circumstances of these measurements (e.g.,
year of measurement, type of weather during
measurement, or the task the measured individ-
ual performed during the measurement) are
used to estimate exposure levels for assignment
unit–time period combinations for which expo-
sure measurements are not available. The strat-
egy used to extrapolate measurements over
assignment unit–time period combinations
determines the validity of the exposure esti-
mates and therefore has a large impact on the
overall quality of the quantiﬁcation of exposure.
In most HOS, exposure measurements are
extrapolated following a set of decision rules
based on expert judgment and/or via a model-
ing framework. A complete and detailed insight
in the applied decision rules in these approaches
is essential for evaluation of HOS.
Type of exposure metric. In an ideal situa-
tion, an exposure metric captures three aspects
that determine exposure: intensity, duration,
and timing (Vacek 1997). The quality of an
exposure metric is based on biologic considera-
tions such as the time window of exposure that
is relevant to the health effect of interest
(Loomis et al. 1998; Seixas et al. 1993; Vacek
1997). A guideline to evaluate HOS based on
the exposure metric used is to compare the
metric used with the current state of knowl-
edge on the nature of the relation between the
exposure and health outcome of interest.
Speciﬁcity of the exposure indicator. In sit-
uations where it is difﬁcult to assess the actual
exposure that is assumed to be causally related
to the health effect of interest, a causal indicator
of exposure, researchers might assess a proxy for
the causal exposure. However, it is crucial that
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Figure 1. Decision pathway of the framework for evaluation of HOS for QRA. Outcomes of the pathway:
exclude study from QRA; study is suitable for QRA; and ranking of a study suitable for QRA based on
study quality.
Tier I: initial evaluation
Selection
Tier II: categorization of study
Tier III: design specific evaluation
Ranking
based on
study
quality
Study is suitable for
quantitative risk
assessment
Exclude study from
quantitative risk
assessment
Ranking of a study suitable for quantitative
risk assessment on study qualitythe proxy exposure is highly correlated to the
exposure of interest. Once absorbed in the
human body, distribution, metabolism, and
excretion have a large impact on the dose of a
specific agent (or metabolite) at the site of
action. Application of exposure indicators capa-
ble of incorporating these biologic inﬂuences in
exposure estimates will result in increased corre-
lation between the exposure indicator and the
dose at the site of action. The application of
biomarkers of exposure in HOS potentially
provides the possibility to obtain exposure indi-
cators with higher specificity compared with
indicators of external exposure. Similar, as with
external exposure, insight in variability of bio-
marker-based exposure measurements is of
utmost importance for QRA.
Blinded exposure assessment. Exposure
assessment should always be performed
blinded for the health outcome of interest to
avoid observer bias. If exposure assessment
was performed on the individual level, omis-
sion of a statement regarding blinded expo-
sure assessment is a reason to exclude HOS
from QRA. If exposure assessment was per-
formed to assess exposure for previously
defined homogeneous exposure categories,
there is no direct connection between the
individuals in the study population and the
exposure assessment, and therefore this
criterion needs less stringent application.
Quality of the exposure assignment
strategy. In the exposure assignment step, expo-
sure levels assessed for specific assignment
unit–time period combinations are translated
into exposure estimates for each individual in
the study population. Assignment is based on
information related to the individuals in the
study population and related to the assignment
unit–time period combinations for which expo-
sure levels have been assessed. Examples of this
information are the jobs an individual per-
formed during his or her working career, a
description of daily diet, or information on
other factors potentially affecting exposure lev-
els. The exposure context in which HOS are
performed determines which type of informa-
tion is available for exposure assignment. A
proper evaluation of the quality of exposure
assignment requires insight in the proportion of
the assignment unit–time period combinations
used for assignment for which no or little expo-
sure measurements were available and exposure
levels had to be inferred. In addition, the over-
lap between the assignment unit–time period
combinations for which exposure measure-
ments were available and the exposure time
periods that are assumed to be relevant to the
assessed health risk needs to be evaluated.
Application of the Guidelines
on Benzene Case–Control and
Cohort Studies
Selection of studies eligible for evaluation. To
test the usefulness and practical implications
of our guidelines, we applied the developed
framework to all case–control and cohort
studies that have reported on a dose–response
relation between exposure to benzene and
acute nonlymphocytic leukemia (ANLL) or
AML. In this example we will ignore the
small differences in disease classification
between ANLL and AML and consider both
as the same health outcome (referred to as
AML). A detailed report of the selection of
publications that were eligible for evaluation
is presented in the Supplemental Material [see
Supplemental Material II, Search Strategy
(http://www.ehponline.org/members/
2008/11530/suppl.pdf) for details]. All iden-
tiﬁed publications were reviewed for eligibility
of application of the evaluation guidelines
(Figure 2). Thirty-two publications were
found not eligible because results from hazard
characterization were not reported. From the
84 publications that did report results from
hazard characterization, 53 publications were
excluded because no quantitative exposure–
response analysis specific for benzene and
leukemia was reported. Finally, 22 publica-
tions did not report results from quantitative
exposure–response analysis specific for ben-
zene and AML. Therefore, the selection strat-
egy resulted in only seven studies eligible for
evaluation. Details of these studies are pre-
sented in Table 2.
Evaluation. A detailed report of the evalu-
ation is presented in the Supplemental
Material [see Supplemental Material III,
Outcome of the Evaluation (http://www.
ehponline.org/members/2008/11530/suppl.
pdf) for details]. Here we discuss the aspects
that contributed to the ranking of the seven
remaining HOS on benzene and AML that
were evaluated with the use of our guidelines.
Vlaanderen et al.
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Table 1. Overview of the criteria used in the three-tiered evaluation of HOS for QRA.a
Tier Evaluation criteria Outcome Impact on evaluation CCb COHc CRd
Ie 1.1 Is the study design case–control, cohort, or cross-sectional? Yes/no Selection for QRAf XX X
Ie 1.2 Is exposure expressed on a ratio scale and speciﬁc for the agent of interest? Yes/no Selection for QRAf XX X
Ie 1.3 Is a detailed description of the statistical analysis provided? Yes/no Selection for QRAf XX X
Ie 1.4 Are criteria for inclusion of subjects into the study described with sufﬁcient detail? Yes/no Selection for QRAf XX X
Ie 1.5 Is the assessment of the health effect performed according to recognized norms? Yes/no Selection for QRAf XX X
Ie 1.6 Are all relevant potential strong confounding factors considered in the study design? Yes/no Selection for QRAf XX X
IIg 2.1 Type of study design Case–control/cohort/ Selection for QRAf/X X X
cross-sectional study quality rankingh
IIIi 3.1 Response rate Numerical Selection for QRAf/X X X
study quality rankingh
IIIi 3.2 Loss to follow-up  Numerical Selection for QRAf/X
study quality rankingh
IIIi 3.3 Minimum follow-up time  Description Selection for QRAf X
IIIi 3.4 Quality of the exposure measurement methods  Description Selection for QRAf/X X X
study quality rankingh
IIIi 3.5 Insight in the variability of exposure  Description Study quality rankingh XX X
IIIi 3.6 Application of exposure measurements in exposure assessment  Description Selection for QRAf/X X X
study quality rankingh
IIIi 3.7 Type of exposure metric Description Study quality ranking h XX X
IIIi 3.8 Speciﬁcity of the exposure indicator Categoryj Study quality ranking h XX X
IIIi 3.9 Blinded exposure assessment Description Selection for QRAf XX X
IIIi 3.10 Quality of the exposure assignment strategy Description Study quality ranking h XX
IIIi 3.11 Potential for information bias Description Study quality ranking h XX X
IIIi 3.12 Blinded health outcome assessment? Description Selection for QRAf XX
IIIi 3.13 Insight in the potential for systematic error in study results  Description Study quality ranking h XX X
aEvaluation criteria are discussed in detail in Supplemental Material I. bCriteria relevant for case–control (CC) study design. cCriteria relevant for cohort study (COH) design. dCriteria
relevant for cross-sectional study (CR) design. eTier I: initial evaluation. fCriteria relevant for selection of HOS for QRA. gTier II: categorization of HOS into three types of study designs
that can potentially be used in QRA. hCriteria relevant for ranking of studies based on quality of design, conduct, and reporting. iTier III: speciﬁc evaluation of the quality of the design,
conduct, and reporting of HOS. jCategories are constructed based on a combination of proxy vs. causal exposure and external vs. internal exposure.Human evidence in quantitative risk assessment
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Definition of minimal requirements for
QRA and identification of potential strong
confounding factors. Before the evaluation,
we defined minimal requirements for inclu-
sion into QRA: response rate > 60%; loss to
follow-up < 10%; and follow-up time > 10
years. We considered exposure to ionizing
radiation as the only factor for which there is
evidence of potential confounding on the
relation between exposure to benzene and
AML (Pagano et al. 2006).
Initial evaluation. Two studies, by
Guénel (Guénel et al. 2002) and Monsanto
(Collins et al. 2003; Ireland et al. 1997), did
not pass the initial evaluation. The Guénel
study was excluded because exposure was not
presented on a ratio scale, but in unit-years
(criterion 1.2). This limitation prohibits the
use of this study in QRA, and therefore fur-
ther evaluation was not done. The Monsanto
study was excluded because of the very lim-
ited information that was provided on the sta-
tistical analysis performed (criterion 1.3). All
other studies passed initial evaluation. It was
assumed that exposure to ionizing radiation
was not above background level in all the
populations studied. Therefore, no potential
strong confounding factors needed to be con-
sidered in the evaluation (criterion 1.6)
Categorization. From the studies that
passed initial evaluation, two were case–con-
trol studies: AHW (Australian Health Watch)
(Glass et al. 2000, 2003, 2005) and U.K.
Petrol (Lewis et al. 1997; Rushton and
Romaniuk 1997), and three were cohort
studies: CAPM-NCI (Chinese Academy of
Medicine–National Cancer Institute)
(Dosemeci et al. 1994; Hayes et al. 1997;
Travis et al. 1994; Yin et al. 1994), Dow
(Bloemen et al. 2004; Ott et al. 1978), and
Plioﬁlm (Paxton et al. 1994a, 1994b; Rinsky
1989; Rinsky et al. 1987; Wong 1995). The
case–control studies were all nested in large
occupational cohorts.
Design-specific evaluation. Design-
speciﬁc criteria that contributed to the ranking
based on quality were related to exposure
assessment, exposure assignment, and insight
in systematic error in exposure assessment/
assignment. All studies (n = 5) reported the
use of exposure measurements in the exposure
assessment. However, there was a wide range
in the amount of information that was pro-
vided regarding the quality of the measure-
ments, insight in the variability of the
measurements, and the use of measurements
in exposure assessment. The AHW study and
the U.K. Petrol study provided the most
detailed information and apparently applied
the most stringent quality criteria for inclusion
of measurements in exposure assessment. The
CAPM-NCI study reported the use of short-
term area measurements but provided very lit-
tle information regarding the quality and
variability of these measurements. The Dow
study reported that an industrial hygienist cat-
egorized all job titles into exposure categories
that were defined in an earlier study on the
same cohort with the use of industrial hygiene
measurements. However, the actual relation
between exposure measurements and exposure
assessment is unclear. The Plioﬁlm study pro-
vided limited information on the measure-
ments used in exposure assessment. However,
it was reported that the measurements used for
Figure 2. Overview of the strategy that was applied
to select publications that report on the relation
between exposure to benzene and AML and are
eligible for evaluation with the guidelines.
116 publications were initially identified
84 publications reported results from hazard
characterization
31 publications reported results from
quantitative exposure–response analysis
specific for benzene and leukemia
9 publications reported results from quantitative
exposure–response analysis specific
for benzene and AML
7 publications were found eligible
for evaulation with the guidelines
2 publications
were excluded
because an
update was
available or the
presented data
was already
reported in a
previous
publication
Table 2. Summary details of the quantitative benzene–AML case–control and cohort studies ranked based on the outcome of the evaluation.
Ranking based 
on evaluation Name of Date of publication of Evaluation outcomes that contributed to
of study quality the study Type of study design  Publications used for evaluation hazard characterization the differentiation of the evaluated HOS
1 U.K. Petrola Nested case–control Lewis et al. 1997; Rushton  1997 + Detailed insight in methodology for assessment
and Romaniuk 1997 and assignment of exposures
+ Limitations of exposure measurements were 
assessed and discussed
+ Potential for systematic error was assessed
2 AHWb Nested case–control Glass et al. 2000, 2003, 2005 2003 + Detailed insight in methodology for assessment 
and assignment of exposures
+ Limitations of exposure measurements were 
assessed and discussed
– Potential for systematic error was not assessed
3 CAPM-NCIc Cohort Dosemeci et al. 1994; Hayes 1997 + Insight in methodology for assessment and
et al. 1997; Travis et al. 1994;  assignment of exposure
Yin et al. 1994 – Limited insight in quality and use of exposure 
measurements
4 Plioﬁlmd Cohort Paxton et al. 1994a, 1994b;  1995 + Insight in methodology for assessment and
Rinsky 1989; Rinsky et al. 1987;  assignment of exposure
Wong and Raabe 1995 – Limited insight in quality and use of exposure 
measurements
5D o w e Cohort Bloemen et al. 2004; Ott et al. 1978 2004 – Limited insight in methodology for assessment and 
assignment of exposure
– Actual use of exposure measurements in exposure 
assessment is unclear
— Guénelf Nested case–control Guénel et al. 2002 2002 Study not suitable for QRA
— Monsantog Cohort Collins et al. 2003; Ireland et al. 1997 2003 Study not suitable for QRA
+, positive study aspect; –, negative study aspect.
aStudy performed on petroleum distribution workers in United Kingdom bAustralian Health Watch study. cStudy performed by Chinese Academy of Preventive Medicine (CAPM) and the
U.S National Cancer Institute (NCI). dStudy performed on workers employed at two Ohio factories producing hydrochloride. eStudy performed on Dow Chemical Michigan Operations
employees. fStudy performed by Guénel et al. on men employed at EDF-GDF. gStudy performed on Monsanto plant employees. the Plioﬁlm cohort reﬂected benzene concen-
trations in workplace area and no personal
sampling was performed. Exposure assignment
strategy was most detailed in the U.K. Petrol,
AHW, and CAPM-NCI studies. These stud-
ies reported the use of job- or task-speciﬁc and
time-speciﬁc information for assignment. The
Pliofilm study applied a less detailed assign-
ment strategy based on a job title–exposure
class matrix and provided limited insight in
the exposure assignment strategy. Dow
reported very limited information regarding
assignment of exposure, which made proper
evaluation impossible. Only one study per-
formed a sensitivity analysis to acquire insight
in the potential of systematic error due to
potential biases such as misclassification of
exposure and quality of work histories used in
assignment (U.K. Petrol).
Ranking of the evaluated studies. Based
on our evaluation, the two case–control stud-
ies, the U.K. Petrol and AHW studies, have
received the highest relative ranking for QRA
(Table 2). Although the study designs of the
U.K. Petrol and AHW studies were compara-
ble, the U.K. Petrol study was ranked higher
because this study reported results from a sen-
sitivity analysis used to evaluate the impact of
several crucial decisions made in the assess-
ment of exposure. The rationale to assign a
lower ranking to the CAPM-NCI and the
Plioﬁlm studies is that in both studies consid-
erable uncertainty existed regarding the quality
of the exposure measurements used and the
methods used to incorporate exposure mea-
surements in the assessment and assignment of
exposures. The CAPM-NCI study provided
more detailed information on the methods
used for exposure assessment and was there-
fore ranked higher than the Pliofilm study.
Although the Dow study was considered suit-
able for QRA, large uncertainty remained
regarding the potential contribution of this
study to QRA. This uncertainty was largely
determined by the lack of information on the
actual use of exposure measurements in assess-
ment and assignment of exposure. Therefore
the Dow study received the lowest ranking.
Discussion of the application of the guide-
lines in the benzene–AML example. In our
example, differentiation of the ﬁve studies suit-
able for QRA was based largely on the quality
of assessment and assignment of exposure. In
general, evaluation was difﬁcult because of the
limited information provided in the evaluated
publications. Therefore, it is possible that the
evaluation outcome of this example is based
partly on the absence of information. Recently,
the STROBE (Strengthening the Reporting of
Observational Studies in Epidemiology) initia-
tive provided general requirements for report-
ing of HOS (Vandenbroucke et al. 2007).
Application of such requirements in the publi-
cation of studies will facilitate the evaluation of
HOS. Unfortunately, STROBE proposes only
limited guidelines for the reporting of exposure
assessment in HOS and is therefore of limited
use for the evaluation of HOS for QRA. In our
example we evaluated only publications pub-
lished in the peer-reviewed scientiﬁc literature.
An alternative approach is to contact the
researchers responsible for the studies selected
for evaluation to acquire as much detailed
information as possible. In our evaluation, each
study included had specific limitations with
regard to the quality of the estimation of quan-
titative exposure levels. As a result of this situa-
tion, several studies have been the subject of
discussion regarding the quality and validity of
exposure estimates (Paustenbach et al. 1992;
Wong 1999). We think that a thorough sensi-
tivity analysis that provides insight in the level
of uncertainty of the estimated exposure levels
and a detailed description of the approach used
for assessment and assignment of exposure
could have left less room for discussion and
thereby would have increased the quality of all
evaluated HOS for QRA. For the design of
future quantitative HOS in this field,
researchers should be aware of the specific
requirements of QRA to HOS with regard to
study design and reporting of results.
Impact for human regulatory risk assess-
ment of benzene. We compared the outcome
of our evaluation with the selection of studies
used in the regulatory QRA performed by the
U.S. Environmental Protection Agency (EPA)
in 1985 and updated in 1998 (U.S. EPA
1998). The U.S. EPA QRA is based on the
study by Rinksy et al. (1987) (Plioﬁlm), Wong
(1987), and Ott et al. (Bond et al. 1986; Ott
et al. 1978) (Dow). A difference between the
U.S. EPA QRA and our evaluation is the
health end point that was considered. Whereas
we evaluated only studies that reported speciﬁc
risk estimates for AML, the U.S. EPA QRA
focused on all leukemias together as a single
health outcome. Therefore, the study by Wong
(1987) was not considered in our evaluation
because this study did not report speciﬁc risk
estimates for AML. Based on our evaluation,
three additional studies should be considered
for a regulatory QRA of benzene: U.K. Petrol,
AHW, and CAPM-NCI. Interestingly, these
three studies were all regarded as providing
higher quality evidence than the Plioﬁlm and
the Dow study using our proposed framework.
To assess the contribution of evidence from a
single HOS to regulatory QRA, the assessment
of the quality of the evidence needs to be com-
bined with an assessment of the relevance of
the evidence for QRA. The combination of
quality and relevance of evidence is deﬁned as
the weight of evidence for QRA (Weed 2005).
Aspects that contribute to the relevance of evi-
dence for QRA are the exposure context in
which the study was performed (e.g., occupa-
tional exposure vs. dietary exposure), the range
of exposure levels included in the study, and
the potential impact of random error on the
study ﬁndings, usually quantiﬁed with conﬁ-
dence intervals (CIs). In Table 3 an overview
Vlaanderen et al.
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Table 3. Aspects that contribute to the relevance of HOS to regulatory QRA.
Exposure context in which Exposure categories included Fold range of the 95% CIs
Name of study the study was performed Size of the study population in study (ppm-years)a reported for relevant risk estimatesb
U.K. Petrol  Occupational exposure 31 cases/121 controls 0.26–0.59 14.6
0.60–1.64 13.3
1.65–4.78 13.2
≥ 4.79 13.4
AHW  Occupational exposure 11 cases/44 controls 4–8 100.0
> 8 31.8
CAPM-NCI Occupational exposure 110,633 individuals (21 cases) < 40 14.0
40–99 14.5
≥ 100 10.5
Plioﬁlm Occupational exposure 1,868 individuals (6 cases) < 40 221
40–200 —c
200–400 29.9
> 400 14.2
Dow Occupational exposure 2,266 individuals (4 cases) < 28.3 28.5
28.3–79.1 204.3
> 79.1 223.8
aExposure categories for which a risk estimate was reported for AML in the evaluated publications. bFold range was calculated as (upper bound of the 95% CI) / (lower bound of the
95% CI) for each exposure group for which a risk estimate was reported for AML in the evaluated publications. cNo cases were observed in this study for this exposure category; there-
fore, the lower bound of the 95% CI was 0 and a fold range could not be calculated.Human evidence in quantitative risk assessment
Environmental Health Perspectives • VOLUME 116 | NUMBER 12 | December 2008 1705
of these aspects that contribute to the relevance
of a study to QRA are presented for the five
studies that we evaluated. In our example all
included studies were performed in the occu-
pational exposure context. However, the U.K.
Petrol, AHW, CAPM-NCI, and Dow studies
included ranges of benzene exposure levels that
are thought to be more relevant for the current
work population and the general population
than the range of exposures that was included
in the Pliofilm study (Table 3). Therefore,
these studies require less extrapolation to calcu-
late relevant risk estimates. To assess the poten-
tial impact of random error on the study
findings, the fold range of the 95% CIs sur-
rounding the relevant risk estimates is reported
for each relevant risk estimate that was
reported in the evaluated studies (Table 3).
Relatively large differences in fold ranges were
observed. We expect that a renewed QRA that
included all quantitative epidemiologic evi-
dence available at this time and incorporated a
weight of evidence approach would signifi-
cantly increase the conﬁdence in unit risk esti-
mates for exposure to benzene. Our approach
contributes to a transparent qualitative insight
in the differences in the weight of evidence of
HOS for QRA. Quantiﬁcation of the weight
of evidence based on a review of the quality
and the relevance of the available studies will
be highly subjective and, if performed at all,
should be as transparent as possible. Although
existing approaches acknowledge the impor-
tance of exposure assessment in HOS for QRA
(Goldbohm et al. 2006; Hertz-Picciotto 1995),
we attempted to improve these methods by
providing a detailed discussion of the aspects
that collectively determine the quality of assess-
ment and assignment of exposure in HOS.
The outcome of the benzene–AML example
indicated that, in this case, there were large dif-
ferences between HOS with regard to the qual-
ity of the exposure assessment that would not
have been detected with the application of the
existing evaluation approaches.
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